Weight stigma, bias, or discrimination based on body size can worsen eating disorders by lowering self-worth, deterring people from seeking care, and reinforcing restrictive or compensatory behaviors
Summary of GLP-1 Hypoglycemic Drugs GLP-1 Activating Drugs directly stimulate GLP-1 receptors, offering benefits like improved insulin secretion, glucagon suppression, appetite control, and weight loss
A related product, Wegovy (semaglutide at higher doses), is specifically indicated for chronic weight management
This process is called gastric emptying, and when it slows down, GLP-1 production speeds up
Memory and learning effects, which depend on BDNF-driven neuroplasticity, take longer to build and are more noticeable at the 3 to 6 week mark
: , LegitScript